February 8, 2019 / 2:26 PM / 5 months ago

BUZZ-Uniqure: Rises on strong updated data from blood clotting disorder therapy study

** Shares of gene therapy developer up 5 pct at $34.2 premarket

** Co says its gene therapy candidate to treat hemophilia B, a genetic disorder that causes excessive bleeding, increased the levels of a protein that helps in blood clotting after 12 weeks in mid-stage study

** Updated data from the study showed that all three patients treated with a single dose of the gene therapy, AMT-061, showed increased and sustained levels of factor IX (FIX), a protein essential for blood clotting - Uniqure

** QURE in Nov 2018 reported preliminary data showing 31 pct rise in FIX activity in the 3 patients who received the AMT-061, six weeks after administration

** After QURE posted early data from the study, several analysts had said QURE’s AMT-061 is a strong competitor to Spark Therapeutics and Pfizer Inc’s gene therapy candidate SPK-9001

** Brokerage Cantor Fitzgerald raises QURE PT to $68 from $65, citing increased probability of success for the hemophilia study

** QURE had surged 47.1 pct in 2018 (Reporting by Manogna Maddipatla)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below